Search the Newsreel

Diabetes and weight-management products using Alina gain European authorizations

Stevanato Group's Alina® pen injector platform has received marketing authorizations in multiple European countries for liraglutide-based combination products used in diabetes and weight management. The approvals for Alina® 30 and Alina® 50 variants highlight the growing demand for injectable therapies, particularly GLP-1 treatments, and …

Janus Henderson Group PLC Sells 354,050 Shares of Corteva, Inc. $CTVA

Janus Henderson Group PLC reduced its stake in Corteva, Inc. by 4.7% in the first quarter, selling 354,050 shares, but still holds over 7.2 million shares valued at $607.2 million. Other institutional investors like William B. Walkup & Associates Inc. and Wilkerson Advisory Group …

181,294 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Acquired by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund has acquired a new stake of 181,294 shares in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), valued at approximately $5.46 million. This purchase is part of broader institutional investment activity, with several other hedge funds also increasing their holdings …

Teva Pharmaceutical Industries (TEVA) Raises Revenue Guidance, Is The 15% Undervaluation Still There?

Teva Pharmaceutical Industries (TEVA) recently raised its 2026 revenue guidance despite reporting a quarterly net loss and asset impairment charges, leading to share price fluctuations. Simply Wall St's analysis suggests the stock is 15.1% undervalued with an implied fair value of $40.90, driven by …

Corteva raises full-year profit forecast, shares fall after revenue miss

Corteva, Inc. (CTVA) has raised its full-year adjusted profit forecast due to strong demand across key crop markets, specifically citing the acreage shift from corn to soybeans. The company now anticipates full-year earnings per share to be between $3.60 and $3.80, up from an …

Corteva Slides as Investors Weigh Post-Separation Risks Ahead of Earnings

Stevanato Group Announces Marketing Authorizations for Liraglutide-Based Combination Products Incorporating Alina Pen Injector in Multiple European Countries

Stevanato Group announced that its liraglutide-based combination products, incorporating the proprietary Alina pen injector, have received marketing authorizations in Europe. These authorizations cover both Alina 30 for diabetes and Alina 50 for weight management, supporting the growing demand for injectable therapies like GLP-1 treatments. …

Teva CEO on Drug Pipeline, Direct Listing on NYSE

Teva Pharmaceuticals CEO Richard Francis speaks to Bloomberg's Romaine Bostick about the company's positive Q2 earnings, the impending impact of changing Medicare rules on patients, and the new listing on the NYSE. View Comments

Teva outlines higher 2026 revenue midpoint by $75M while targeting AUSTEDO $2.45B-$2.6B and AJOVY $850M-$870M

Earnings Call Insights: Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 MANAGEMENT VIEW * "On delivery on our growth engines, AUSTEDO, AJOVY, and UZEDY all delivered strong Q2 performance, and we are raising our full-year revenue guidance for these products." (President, CEO & Director Richard …

Teva Stock Rises After Earnings as Revenue Guidance Exceeds Expectations

Teva Pharmaceutical Industries' stock rose following its second-quarter earnings report. Investors focused on the company's updated full-year revenue guidance, which exceeded expectations, despite mixed earnings results.

Teva Pharmaceutical Industries Ltd (TEVA) Q2 2026 Earnings Call Highlights: Strong Innovative ...

This article first appeared on GuruFocus. Revenue: Approximately $4.1 billion, down 1% in U.S. Dollars or 3% in local currency compared to Q2 2025. Net Loss: $576 million. Non-GAAP Gross Margin: 55.4%, an increase of 80 basis points year-over-year. Non-GAAP Operating Margin: 9%, including …

Teva Pharmaceutical Industries Sees Unusually High Options Volume (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) experienced an unusually high volume of call option trading, with 23,688 call options purchased, significantly above its daily average. This surge in options activity suggests increased bullish speculation, despite the company reporting mixed financial results with revenue exceeding estimates but …

Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views

Teva Pharmaceutical Industries climbed above an important chart level Wednesday, after the company's bullish guidance overshadowed mixed second-quarter results. Teva earnings thinned to 2 cents a share after subtracting costs from an acquisition. The profit came in below the consensus estimate of 5 cents …

Is CTVA Stock Worth Buying After a Powerful Rally and Earnings Beat?

Corteva (CTVA) has seen a 32.7% year-to-date gain, fueled by a strong earnings beat and improved operating outlook. While the company's Q1 2026 operating earnings significantly surpassed expectations, its valuation trades at a premium compared to industry benchmarks and its historical median. Despite a …

Why Corteva's Seed and Crop Protection Engines Matter to Investors

The article discusses why Corteva's two main business segments, Seed and Crop Protection, are important to investors, especially with a planned separation in late 2026. It highlights the distinct earning drivers of each segment, their performance in Q1 2026, and the company's cost-saving measures. …

How Corteva's Innovation Pipeline Could Shape Its Next Growth Cycle

Corteva is leveraging technology to drive its next growth cycle, focusing on new crop protection products and seed innovations. The company aims to achieve $2 billion in new crop protection revenues by 2026 and expects its seed business to become royalty positive in the …

Teva Shares Climb as Revenue Beat and Innovative Drug Growth Offset Earnings Miss

Researcher with pipette ©National Institutes of Health Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported mixed second-quarter results, with revenue exceeding Wall Street expectations while adjusted earnings fell short due to acquisition-related costs. Investors focused on the company's strong sales growth from its key branded medicines, …

Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Teva Pharmaceutical Industries Ltd. (TEVA) reported $4.14 billion in revenue for the quarter ended June 2026, representing a year-over-year decline of 0.8%. EPS of $0.02 for the same period compares to $0.66 a year ago. The reported revenue represents a surprise of +1.43% over …

UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook

MONTPELLIER, France, July 29, 2026--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 …

Teva shares rise 3% on Q2 top-line beat as key brands deliver strong performance

Teva Pharmaceutical Industries Ltd. reported mixed Q2 results, with revenue exceeding expectations at $4.14 billion due to strong performance from key innovative brands like AUSTEDO, AJOVY, and UZEDY. Despite an adjusted EPS miss ($0.02 vs. $0.62 consensus) largely due to acquisition expenses, shares rose …

Teva Pharmaceutical Industries Releases Q2 2026 Financial Results

Teva Pharmaceutical Industries Limited reported a significant earnings miss for Q2 2026, with non-GAAP diluted earnings of $0.02 per share against a $0.32 estimate, missing by 93.8%. The company's revenue for the quarter was $4.14B, a 1.0% decrease year-over-year, largely due to a 5.0% …

Teva stock gains after Q2 revenue beat (TEVA:NYSE)

Teva Pharmaceutical (TEVA) saw its stock increase by approximately 3% in premarket trading after reporting better-than-expected Q2 2026 revenues, despite a decline in generic product sales. The company also announced plans for a direct NYSE listing, aiming to expand its shareholder base and reduce …

Earnings Flash (TEVA) Teva Pharmaceutical Industries Ltd. Reports Q2 Revenue $4.14B, vs. FactSet Est of $4.02B

Teva Pharmaceutical Industries Ltd. (TEVA) announced its Q2 revenue at $4.14 billion, surpassing FactSet estimates of $4.02 billion. The company also updated its earnings and revenue guidance for the full year 2026, despite reporting lower Q2 adjusted earnings and revenue. Teva's CEO also indicated …

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

Teva Pharmaceutical Industries Ltd Q2 2026 revenues of $4.1 billion decreased by 1% in U.S. dollars year-over-year (YoY) and by 3% in local currency (LC) terms, mainly due to lower generics revenues. Our key innovative brands collectively grew 43% YoY in LC, to over …

Teva Pharmaceutical Industries (NYSE: TEVA) Q2 loss while raising brand outlook

Teva Pharmaceutical Industries reported a Q2 2026 GAAP net loss of $576 million but maintained its full-year revenue and free cash flow guidance, while raising the outlook for its key innovative brands (AUSTEDO, AJOVY, and UZEDY) to approximately $3.7 billion. The loss was primarily …

Corteva, Inc. $CTVA Shares Bought by Royal Bank of Canada

Royal Bank of Canada significantly increased its stake in Corteva, Inc. (NYSE:CTVA) by 202.1% in the first quarter, now owning 7,458,624 shares valued at over $624 million. Other institutional investors also adjusted their holdings in Corteva, with hedge funds and institutional investors owning 81.54% …

Corteva, Inc. $CTVA Stock Holdings Lowered by California State Teachers Retirement System

California State Teachers Retirement System reduced its holdings in Corteva, Inc. (CTVA) by 1.7% in the first quarter, selling 30,311 shares but still holding 1.80 million shares valued at about $150.8 million. Despite this reduction, analysts maintain a "Moderate Buy" rating with an average …

‘It is okay not to be okay’: NFL legend Terrell Davis joins growing roster of athletes partnering with big pharma to raise health awareness

For decades, pharmaceutical advertising largely revolved around television commercials urging patients to ask their doctors about branded medication. Increasingly, however, drugmakers are investing in a different kind of marketing campaign—one built around trusted athletes who have publicly discussed their own health struggles. The latest …

Teva Stock Rises After Earnings as Revenue Guidance Exceeds Expectations -- Barrons.com

Teva stock advances after the pharmaceutical company reports mixed second-quarter earnings but raises its full-year revenue outlook. Continue Reading

Corteva Inc (CTVA) Institutional Confidence

Corteva Inc (CTVA) has an institutional shareholding score of 7.00, placing it 28th out of 65 in the Chemicals industry. The institutional shareholding proportion recently increased by 0.29% to 89.59%. David G. Herro is the largest institutional shareholder, holding 17.40 million shares, which represents …

Teva Stock Is Rebounding. Its Drug Pipeline Holds the Key to Growth.

Teva can look beyond President Donald Trump’s threat of a tariff on generic drugs. Teva has a pipeline of branded drugs that has caught Wall Street’s attention. Continue Reading

TEVA Looks 55.9% Overvalued on GF Value™ as Earnings Outlook Dims

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is projected to report a significant 83% drop in Q2 2026 earnings per share and a 4% revenue decline. Despite beating expectations in the previous quarter, the company lowered full-year guidance due to an acquisition and faces ongoing …

Teva Pharmaceutical Inds Number of Employees 2026 | Employee Count & Headcount Data

Teva Pharmaceutical Industries Ltd. (TEVA) had approximately 33,327 employees worldwide as of March 2026, marking a 2.8% decline from 2023. The company is actively hiring with 968 job postings in 2026, a 3.7% increase from the previous year, and its workforce is concentrated in …

Corteva Number of Employees 2026 | Employee Count & Headcount Data

Corteva, Inc. (CTVA) had approximately 21,683 total employees worldwide as of March 2026, marking a 1.2% growth from 2023. The company is actively hiring, with 602 active job postings in 2026, though this represents a 41.0% decline from 2025. The workforce is primarily concentrated …

Piper Sandler Raises Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $44.00

Piper Sandler has increased its price target for Teva Pharmaceutical Industries (NYSE:TEVA) to $44.00 from $42.00, maintaining an "overweight" rating and suggesting a potential upside of over 40% from its current price. This follows a trend of positive analyst sentiment, with a consensus "Moderate …

Corteva, Inc. (CTVA) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

Corteva, Inc. (CTVA) is expected to announce Q2 earnings of $2.24 per share, a 1.8% increase year-over-year, with revenues forecasted at $6.62 billion, up 2.6%. Despite these positive headline figures, the consensus EPS estimate has seen a significant 89.9% downward revision in the past …